Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd. (India) holds 278 active US FDA Type II Drug Master Files and 90 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 10 FDA-registered manufacturing sites. 42 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Dr. Reddy's Laboratories Ltd.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/dr-reddy-s-laboratories-ltd
Overview
Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company based in India, engaged in providing affordable and innovative medicines. The company offers a wide portfolio of products and services, including pharmaceutical generics, active pharmaceutical ingredients, biosimilars, and differentiated formulations.
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Dr. Reddy's Laboratories Ltd. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Dr. Reddy's Laboratories Ltd. holds 278 active (368 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- LENACAPAVIR SODIUMActive2026-09-30
- TAFAMIDIS (FORM-1)Active2026-07-15
- PENTOSAN POLYSULFATE SODIUMActive2026-03-31
- TAFAMIDISActive2026-03-31
- TIRZEPATIDEActive2026-03-31
- PIRTOBRUTINIBActive2026-03-31
- ADAGRASIBActive2026-03-31
- ALECTINIB HYDROCHLORIDEActive2026-03-31
- FINASTERIDE - USP (FORM-I)Active2026-03-31
- PERFLUOROHEXYLOCTANEActive2026-03-30
- DAPAGLIFLOZIN PROPANEDIOL (DPD-1)Active2026-03-30
- EMPAGLIFLOZIN (EFG)Active2026-03-20
- DEUCRAVACITINIB PREMIXActive2026-02-27
- RIVAROXABAN USP [PROCESS-II]Active2025-12-31
- NILOTINIB PREMIX (HPMC AS)Active2025-12-30
- ATORVASTATIN CALCIUM TRIHYDRATE [FORM-I] USP [AFP PROCESS]Active2025-12-30
- TUCATINIB COPOVIDONE ASDActive2025-08-19
- EDOXABAN TOSYLATE MONOHYDRATEActive2025-07-29
- FINERENONEActive2025-03-31
- TUCATINIB HEMIETHANOLATEActive2025-03-31
- TUCATINIBActive2025-03-28
- DEUCRAVACITINIBActive2025-03-28
- ENZALUTAMIDE PREMIX (20% W/W)Active2025-03-27
- NIRAPARIB TOSYLATE MONOHYDRATEActive2025-03-27
- TIZANIDINE HYDROCHLORIDE USP (TZN-PROCESS)Active2025-03-24
- MAVACAMTENActive2024-12-31
- VOCLOSPORINActive2024-12-31
- ABEMACICLIBActive2024-12-31
- DABIGATRAN ETEXIATE MESYLATE (PROCESS-II) USPActive2024-09-30
- SITAGLIPTIN PHOSPHATE MONOHYDRATE (PRODUCT CODE: SPT-4)Active2024-09-27
- SACUBITRIL SODIUMActive2024-08-28
- LANREOTIDE ACETATEActive2024-06-28
- RUXOLITINIB PHOSPHATEActive2024-03-27
- RELUGOLIXActive2024-03-20
- VONOPRAZAN FUMARATEActive2024-02-29
- RUXOLITINIB HEMIFUMARATEActive2024-02-29
- RUXOLITINIBActive2024-02-28
- RIPRETINIBActive2024-02-23
- EZETIMIBEActive2023-12-29
- CABOZANTINIB (S)-MALATE (FORM N-2)Active2023-12-29
- CABOZANTINIB INTERMEDIATE (CZT3)Active2023-12-01
- OMEPRAZOLE MAGNESIUM (CRYSTALLINE)Active2023-09-29
- VARENICLINE TARTRATEActive2023-08-30
- LUMATEPERONE TOSYLATEActive2023-03-31
- CABOZANTINIB HYDROCHLORIDEActive2023-03-31
- FERRIC CARBOXYMALTOSEActive2023-03-29
- (R)-3-(TERT-BUTOXYCARBONYLAMINO)-4-(2,4,5-TRIFLUOROPHENYL)BUTANOIC ACIDActive2023-03-29
- FOSAPREPITANT DIMEGLUMINEActive2023-03-28
- TAFAMIDIS MEGLUMINEActive2023-02-21
- EMPAGLIFLOZIN AMORPHOUS (PRODUCT CODE: EGF9)Active2022-12-29
Showing the 50 most relevant of 368 Drug Master Files (active first). The full list is in the FDA DMF list.
Excipient Drug Master Files
Dr. Reddy's Laboratories Ltd. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- SALCAPROZATE SODIUMActive2023-03-31
Registered manufacturing sites (10)
Physical sites registered with the US FDA and resolved to Dr. Reddy's Laboratories Ltd., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- Dr. Reddy's Laboratories (EU) Ltd.MIRFIELD, United Kingdom · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDSrikakulam, India · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDNalgonda, India · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDSangareddy, India · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDSangareddy, India · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDSrikakulam, India · API manufacture
- DR. REDDY'S LABORATORIES LIMITEDSangareddy, India · API manufacture
- DR.REDDY'S LABORATORIES LIMITEDVisakhapatnam, India · Analytical testing · Drug manufactureSite GMP match
- DR.REDDY'S LABORATORIES LIMITEDMedchal-Malkajgiri, India · API manufactureSite GMP match
- Industrias Qu�micas Falc�n de M�xico, S.A. de C.V. (DR. REDDY'S MEXICO)MORELOS, Mexico · API manufacture
FDA compliance signals
42 FDA enforcement records linked to this company.
- 4832024-05-17
Cleaning / Sanitizing / Maintenance
- 4832024-05-17
Procedures for sterile drug products
- 4832023-10-27
Investigations of discrepancies, failures
- 4832023-10-27
Instruments, apparatus, et. al. not meeting specs
- 4832023-10-27
Cleaning / Sanitizing / Maintenance
- 4832023-10-27
Acceptance of drug products
- 4832023-10-27
Test methods
- 4832023-10-27
Buildings not maintained in good state of repair
- 4832023-10-27
Absence of Written Procedures
- 4832023-10-27
Computer control of master formula records
- 4832023-10-27
Procedures not in writing, fully followed
- 4832023-10-27
Complaint Handling Procedure
- recall — Class II2023-07-26
Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.
- 4832019-02-08
Reserve samples identified, representative, stored
- 4832019-02-08
In process materials - conformance to written specs
- 4832019-02-08
Procedures not in writing, fully followed
- 4832019-02-08
Complaint Handling Procedure
- 4832019-02-08
Adequate space lacking to prevent mix-ups and contamination
- 4832019-02-08
Computer control of master formula records
- 4832019-02-08
Complete instructions, procedures, specifications et. al.
- 4832019-02-08
Approve or reject components, products
- 4832019-02-08
Drains--Size, Back-siphonage Prevention
- 4832019-02-08
Authority lacking to review records, investigate errors
- 4832019-02-08
Adequate lab facilities not available
- 4832019-01-15
Investigations of discrepancies, failures
- 4832019-01-15
Scientifically sound laboratory controls
- 4832019-01-15
Computer control of master formula records
- 4832019-01-15
SOPs not followed / documented
- 4832017-04-28
Authority lacking to review records, investigate errors
- 4832017-04-28
Establish reliability of supplier's C of A
- 4832017-04-28
Annual visual exams of drug products
- 4832017-04-28
Supervisor Training/Education/Experience
- 4832017-04-28
Training , Education , Experience overall
- 4832017-04-28
Complete Test Data
- 4832017-04-28
Testing and release for distribution
- 4832017-04-28
Scientifically sound laboratory controls
- 4832017-04-28
Backup data not assured as exact and complete
- 4832017-04-28
Procedures not in writing, fully followed
- 4832017-04-28
Calibration/Inspection/Checking not done
- warning_letter2015-11-05
FDA Warning Letter (drug product)
- warning_letter2015-11-05
FDA Warning Letter (drug product)
- recall — Class III2013-04-10
Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Is this Dr. Reddy's Laboratories Ltd.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.